Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant short-course radiotherapy plus XELOX chemotherapy and immunotherapy in mid-low locally advanced rectal cancer
ChiCTR2600119083Phase 2Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, camrelizumab, oxaliplatin and capecitabine in rectal adenocarcinoma, sponsored by Beijing Friendship Hospital. Primary endpoint: Complete response rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
cadonilimabcamrelizumaboxaliplatincapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600119083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119083.